Traders Union
All News
Cell therapy, immuno-oncology, and biotech innovation by Artiva Biotherapeutics

Advertiser Disclosure

Cell therapy, immuno-oncology, and biotech innovation by Artiva Biotherapeutics

FDA awards Artiva Biotherapeutics, Inc. RMAT status for AlloNK combination therapy in rheumatoid arthritis

Ivan Andriyenko
08.06.2026

FDA awards Artiva Biotherapeutics, Inc. RMAT status for AlloNK combination therapy in rheumatoid arthritis

Artiva Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its AlloNK product in combination with ...

$Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis$

Andreas Kristo
04.06.2026

Artiva Biotherapeutics aims for first Phase 3 trial targeting B-cell depletion in refractory rheumatoid arthritis

Artiva Biotherapeutics, Inc. has announced a focused strategy to advance its AlloNK therapy as it prepares for its first Phase 3 registrational trial. The company is positioning AlloNK as a ...

Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event

Oleg Tkachenko
28.05.2026

Artiva Biotherapeutics, Inc. to outline AlloNK Phase 3 progress at New York Jefferies event

Artiva Biotherapeutics, Inc. will participate in the 2026 Jefferies Global Healthcare Conference in New York, with CEO Fred Aslan, M.D., slated for a fireside chat on Thursday, June 4, from 9:20 ...

Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases

Ivan Andriyenko
19.05.2026

Artiva Biotherapeutics, Inc. to present five abstracts on AlloNK at EULAR 2026 across multiple diseases

Artiva Biotherapeutics, Inc. will unveil five accepted abstracts featuring its AlloNK therapeutic at EULAR 2026. These presentations will cover clinical and translational findings across ...

$Artiva Biotherapeutics, Inc. to start Phase 3 AlloNK trial in refractory RA after strong early results$

Artem Shendetskii
08.05.2026

Artiva Biotherapeutics, Inc. to start Phase 3 AlloNK trial in refractory RA after strong early results

Artiva Biotherapeutics, Inc. has announced positive initial clinical results for its AlloNK cell therapy across multiple autoimmune diseases. The company also shared that it reached alignment ...

Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026

Yulia Slavina
10.03.2026

Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026

Artiva Biotherapeutics reported full year 2025 financial results and outlined progress on its AlloNK program for autoimmune diseases. The company expects initial clinical response data from at ...

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.